Benitec Biopharma Inc.
BNTC
$12.37
-$0.63-4.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 17.70% | -23.92% | -77.21% | -242.10% | -238.89% |
| Total Depreciation and Amortization | 12.26% | 48.15% | 29.67% | 29.67% | 17.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.96% | 210.83% | 1,090.80% | 2,862.78% | 3,933.33% |
| Change in Net Operating Assets | -106.40% | 192.74% | 696.23% | -738.89% | 264.21% |
| Cash from Operations | -44.26% | 50.98% | 26.93% | -149.41% | 49.97% |
| Capital Expenditure | -150.00% | 8.33% | -- | -- | 96.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -150.00% | 8.33% | -- | -- | 96.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.34% | 484.69% | -- | -1.61% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.96% | -313,150.00% | -- | -1,241.46% | -5,856.41% |
| Cash from Financing | -98.21% | 449.69% | -- | -93.65% | -- |
| Foreign Exchange rate Adjustments | -219.05% | -146.32% | 190.53% | -2,300.00% | -118.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -116.05% | 803.36% | -119.23% | -115.74% | 502.78% |